Drug Trial Radar · NCT07137104
Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Aug 27, 2026
Primary completion
Dec 31, 2028
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Hexun Biosciences Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.
Conditions
- Coronary Artery Disease
Interventions
HeXell-2020Drug
Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose. Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose. Phase IIa: RP2D from phase I.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAE, SAE and SUSAR over the studyTime frame: Within the first year after cell transplantaion
- To determine the recommended phase II dose (RP2D) in Phase I studyTime frame: Within the first year after cell transplantaion
- Change in myocardial perfusion defect severity under the rest acquisition and pharmacological stress of dipyridamole in Phase IIa studyTime frame: Before first dosing and at 12 months post cell transplantaion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Far Eastern Memorial Hospital
New Taipei City, Banqiao Dist, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.